Tirzepatide

Tirzepatide Peptide is a dual incretin peptide that activates both the GLP 1 and GIP receptors, two hormonal pathways the body already uses to regulate appetite, insulin response, and energy balance. Rather than introducing a foreign stimulant or fat burner, Tirzepatide works by amplifying and coordinating existing metabolic signalling systems that control glucose handling and body weight.

Tirzepatide peptide is FDA approved in the United States and is commercially known under brand names such as Mounjaro and Zepbound. It has completed multiple large scale Phase 3 clinical trials and is widely regarded as one of the most effective compounds ever developed for weight loss and metabolic disease research. In obesity focused studies, Tirzepatide demonstrated average weight loss of approximately 15 to 22 percent of total body weight over 72 weeks, significantly outperforming earlier single pathway incretin therapies.

The strength of Tirzepatide lies in its dual GLP 1 and GIP mechanism. GLP 1 signalling reduces appetite, slows gastric emptying, and improves satiety, while GIP signalling enhances insulin sensitivity and influences fat metabolism at the tissue level. Together, these pathways create a coordinated metabolic response that supports sustained weight loss rather than short term appetite suppression alone.

Because these incretin hormones already exist within the body, Tirzepatide functions as a metabolic messenger, reinforcing signals the body recognises instead of forcing an artificial response. This has positioned Tirzepatide as a cornerstone compound in research focused on obesity, insulin resistance, type 2 diabetes, and long term body weight regulation.

Baseline Labs Tirzepatide is supplied as a high purity, lyophilized peptide, produced under strict quality controls with clear and consistent labelling. Each vial contains a single, unblended compound with no fillers, no blends, and no ambiguous concentrations. Where applicable, quality documentation is provided to support transparency and verification.

Tirzepatide is not a stimulant and does not rely on acute metabolic stress. Its effects are hormonal and signalling driven, making it particularly relevant for research models examining durable weight loss, appetite regulation, and metabolic correction rather than short lived dieting effects.

Product details
• Compound Tirzepatide
• Form Lyophilized peptide
• Packaging Single sealed vial
• Supplied by Baseline Labs

This product is supplied without dosing instructions or usage guidance. No medical or therapeutic claims are made or implied.

Intended use
Tirzepatide from Baseline Labs is supplied for laboratory and investigational research purposes. It is intended for experienced and informed purchasers who understand proper handling, storage, and research context.

Tirzepatide Certificate of Analysis PDF